Eli Lilly and Company (LLY)

Check out top investors' recommendation for LLY
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; bipolar depression and treatment-resistant depression; and brain imaging of beta-amyloid plaques. Its endocrinology products treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. The company’s oncology products treat malignant pleural mesothelioma; pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as cardiovascular products, which are used treat erectile dysfunction, benign prostatic hyperplasia, high cholesterol, pulmonary arterial hypertension; reduce thrombotic cardiovascular events; and used as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to improve milk productivity in dairy cows; anticoccidial agents; antibiotics to control enteric infections in calves and swine; products to treat canine separation anxiety; products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections; and other pharmaceutical products to treat staphylococcal and bacterial infections. The company distributes its products through independent wholesale distributors; and directly to pharmacies. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Vamil Divan Credit Suisse Sell   Jun 21, '18     84.00  Jun 21, '19  N/A 
Chris Schott JPMorgan Buy   Jun 11, '18     100.00  Jun 11, '19  N/A 
Louise Chen Guggenheim Securities LLC Buy   Jun 07, '18     100.00  Jun 07, '19  N/A 
Geoff Meacham JPMorgan Buy   May 22, '18     98.00  May 22, '19  N/A 
John Boris Citi Buy   Apr 05, '18     101.00  Apr 05, '19  N/A 
Alex Arfaei BMO Capital Markets Sell   Apr 04, '18     74.00  Apr 04, '19  N/A 
Chris Schott JPMorgan Buy   Feb 26, '18     105.00  Feb 26, '19  N/A 
Vamil Divan Credit Suisse Sell   Jan 22, '18     82.00  Jan 22, '19  N/A 
Jeffrey Holford Jefferies & Co. Buy   Jan 16, '18     100.00  Jan 16, '19  N/A 
Alex Arfaei BMO Capital Markets Sell   Jan 10, '18     73.00  Jan 10, '19  N/A 
David Toung Argus Research Company Buy   Jan 05, '18     115.00  Jan 05, '19  N/A 
Jeffrey Holford Jefferies & Co. Buy   Nov 16, '17     95.00  Nov 16, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   Nov 13, '17     73.00  Nov 13, '18  N/A 
John Boris Citi Buy   Oct 27, '17     101.00  Oct 27, '18  N/A 
Richard Purkiss Atlantic Equities Buy   Oct 24, '17     107.00  Oct 24, '18  N/A 
Jeffrey Holford Jefferies & Co. Buy   Oct 16, '17     100.00  Oct 16, '18  N/A 
David Amsellem Piper Jaffray Buy   Oct 12, '17     105.00  Oct 12, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   Oct 09, '17       Oct 09, '18  N/A 
Jami Rubin Goldman Sachs Buy   Oct 05, '17     95.00  Oct 05, '18  N/A 
Steve Scala Cowen And Company Buy   Oct 03, '17     95.00  Oct 03, '18  N/A 
< previous12345